Literature DB >> 30834549

Cerebrospinal fluid exposure of cenicriviroc in HIV-positive individuals with cognitive impairment.

Jasmini Alagaratnam1,2, Sujan Dilly-Penchala3, Elizabeth Challenger3, Laura Else3, Ken Legg1, Claire Petersen1, Brynmor Jones2, Ranjababu Kulasegaram4, Star Seyedkazemi5, Eric Lefebvre5, Saye Khoo3, Alan Winston1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30834549      PMCID： PMC6475690          DOI： 10.1111/bcp.13878

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  5 in total

1.  Cerebrospinal fluid exposure of cenicriviroc in HIV-positive individuals with cognitive impairment.

Authors:  Jasmini Alagaratnam; Sujan Dilly-Penchala; Elizabeth Challenger; Laura Else; Ken Legg; Claire Petersen; Brynmor Jones; Ranjababu Kulasegaram; Star Seyedkazemi; Eric Lefebvre; Saye Khoo; Alan Winston
Journal:  Br J Clin Pharmacol       Date:  2019-03-04       Impact factor: 4.335

2.  The PHQ-9: validity of a brief depression severity measure.

Authors:  K Kroenke; R L Spitzer; J B Williams
Journal:  J Gen Intern Med       Date:  2001-09       Impact factor: 5.128

3.  Improved Cognitive Performance and Reduced Monocyte Activation in Virally Suppressed Chronic HIV After Dual CCR2 and CCR5 Antagonism.

Authors:  Michelle L DʼAntoni; Robert H Paul; Brooks I Mitchell; Lindsay Kohorn; Laurent Fischer; Eric Lefebvre; Star Seyedkazemi; Beau K Nakamoto; Maegen Walker; Kalpana J Kallianpur; Debra Ogata-Arakaki; Lishomwa C Ndhlovu; Cecilia Shikuma
Journal:  J Acquir Immune Defic Syndr       Date:  2018-09-01       Impact factor: 3.731

4.  Blood Brain Barrier Impairment in HIV-Positive Naïve and Effectively Treated Patients: Immune Activation Versus Astrocytosis.

Authors:  A Calcagno; A Romito; C Atzori; V Ghisetti; C Cardellino; S Audagnotto; E Scarvaglieri; F Lipani; D Imperiale; G Di Perri; S Bonora
Journal:  J Neuroimmune Pharmacol       Date:  2016-11-08       Impact factor: 4.147

5.  A 48-week randomized phase 2b study evaluating cenicriviroc versus efavirenz in treatment-naive HIV-infected adults with C-C chemokine receptor type 5-tropic virus.

Authors:  Melanie Thompson; Michael Saag; Edwin DeJesus; Joseph Gathe; Jay Lalezari; Alan L Landay; Jerry Cade; Jeffrey Enejosa; Eric Lefebvre; Judith Feinberg
Journal:  AIDS       Date:  2016-03-27       Impact factor: 4.177
  5 in total
  2 in total

1.  Cerebrospinal fluid exposure of cenicriviroc in HIV-positive individuals with cognitive impairment.

Authors:  Jasmini Alagaratnam; Sujan Dilly-Penchala; Elizabeth Challenger; Laura Else; Ken Legg; Claire Petersen; Brynmor Jones; Ranjababu Kulasegaram; Star Seyedkazemi; Eric Lefebvre; Saye Khoo; Alan Winston
Journal:  Br J Clin Pharmacol       Date:  2019-03-04       Impact factor: 4.335

2.  Identification of Molecular Signatures and Candidate Drugs in Vascular Dementia by Bioinformatics Analyses.

Authors:  Jun Shu; Wenshi Wei; Li Zhang
Journal:  Front Mol Neurosci       Date:  2022-02-11       Impact factor: 5.639
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.